CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02742727|
Recruitment Status : Unknown
Verified December 2016 by PersonGen BioTherapeutics (Suzhou) Co., Ltd..
Recruitment status was: Recruiting
First Posted : April 19, 2016
Last Update Posted : December 6, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia Precursor T-Cell Lymphoblastic Leukemia-Lymphoma T-cell Prolymphocytic Leukemia T-cell Large Granular Lymphocytic Leukemia Peripheral T-cell Lymphoma, NOS Angioimmunoblastic T-cell Lymphoma Extranodal NK/T-cell Lymphoma, Nasal Type Enteropathy-type Intestinal T-cell Lymphoma Hepatosplenic T-cell Lymphoma||Biological: anti-CD7 CAR-pNK cells||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||March 2017|
|Estimated Study Completion Date :||March 2018|
Experimental: CAR-pNK Cell immunotherapy
Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
Biological: anti-CD7 CAR-pNK cells
The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
Other Name: chimeric antigen receptor NK cells with specificity for CD7
- Adverse events attributed to the administration of the anti-CD7 CAR-pNK cells [ Time Frame: 2 years ]Determine the toxicity profile of the CD7 targeted CAR-pNK cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
- Clinical response to CD7 CAR-pNK cell infusions [ Time Frame: Safety follow-up is 100 days from last CAR-pNK infusion ]Patients with measurable disease will be assessed for the response of their disease to CD7 CAR-pNK cell treatment.
- Determine the existence of CD7-CAR-pNK in vivo [ Time Frame: 1 year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Male and female subjects with CD7+ malignancies in patients with no available curative treatment options who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled:
- Eligible diseases: CD7 positive relapsed or refractory Leukemia and Lymphoma. ￚ Acute myeloid leukemia, previously identified as CD7+ ￚ Precursor T lymphoblast leukemia/lymphoma ￚ T-cell prolymphocytic leukemia ￚ T-cell large granular lymphocytic leukemia ￚ Peripheral T-cell lymphoma, NOS ￚ Angioimmunoblastic T-cell lymphoma ￚ Extranodal NK/T-cell lymphoma, nasal type ￚ Enteropathy-type intestinal T-cell lymphoma ￚ Hepatosplenic T-cell lymphoma
- Patients 18 years of age or older, and must have a life expectancy > 12 weeks.
- CD7 is expressed in malignancy tissues by immuno-histochemical (IHC) or Flow cytometry.
- Assessable disease as measured by laboratory and bone marrow examinations.
- Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky performance status (KPS) score is higher than 60.
- Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of CAR-pNK cells.
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration.
- Ability to give informed consent.
- Patients with symptomatic central nervous system (CNS) involvement.
- Pregnant or nursing women may not participate.
- Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Previously treatment with any gene therapy products.
- The existence of unstable or active ulcers or gastrointestinal bleeding.
- Patients with a history of organ transplantation or are waiting for organ transplantation.
- Patients need anticoagulant therapy (such as warfarin or heparin).
- Patients need long-term antiplatelet therapy (aspirin at a dose > 300mg/d; clopidogrel at a dose > 75mg/d).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02742727
|Contact: Lin Yang, Ph.D.||firstname.lastname@example.org|
|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||Recruiting|
|Suzhou, Jiangsu, China, 215123|
|Contact: Lin Yang, Ph.D. 86-512-65922190 email@example.com|
|Principal Investigator: Yangyi Bao, MD|
|Principal Investigator: Xiang Sun, MD|
|Principal Investigator: Lin Yang, Ph.D|
|Principal Investigator:||Lin Yang, Ph.D.||PersonGen BioTherapeutics (Suzhou) Co., Ltd.|
|Responsible Party:||PersonGen BioTherapeutics (Suzhou) Co., Ltd.|
|Other Study ID Numbers:||
|First Posted:||April 19, 2016 Key Record Dates|
|Last Update Posted:||December 6, 2016|
|Last Verified:||December 2016|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
Lymphoma, T-Cell, Peripheral
Lymphoma, Extranodal NK-T-Cell
Leukemia, Large Granular Lymphocytic
Leukemia, Prolymphocytic, T-Cell
Enteropathy-Associated T-Cell Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Immune System Diseases
Precursor Cell Lymphoblastic Leukemia-Lymphoma